AstraZeneca Halts Major Investment in Cambridge Amid Economic Uncertainty

AstraZeneca has paused plans for a £200 million investment at its Cambridge research site, which would have created 1,000 jobs. This follows its canceled £450 million investment in northern England due to reduced UK government support. Merck also abandoned plans for a London research center.

AstraZeneca Halts Major Investment in Cambridge Amid Economic Uncertainty
This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

AstraZeneca, Britain's largest company by market capitalization, has announced a pause on its planned £200 million investment in a Cambridge research facility, citing ongoing reassessments of investment needs, a spokesperson confirmed.

The halted investment, initially intended to create 1,000 jobs, follows AstraZeneca's earlier decision to cancel a £450 million investment in a vaccine manufacturing plant in northern England. The company attributed the decision to a reduction in support from the UK government.

This move comes on the heels of Merck & Co's recent announcement to abandon its planned research center in London, further spotlighting the UK's challenging business environment for the pharmaceutical industry.

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.